ALLIANCEBERNSTEIN L.P. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 136 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.1%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$93,589,325
-14.4%
1,366,467
-13.6%
0.03%
-15.4%
Q1 2024$109,385,409
-15.2%
1,580,714
-12.3%
0.04%
-22.0%
Q4 2023$129,061,174
+30.8%
1,802,027
-4.8%
0.05%
+19.0%
Q3 2023$98,650,178
-23.7%
1,893,841
-7.2%
0.04%
-20.8%
Q2 2023$129,223,583
+19.1%
2,040,802
+1.9%
0.05%
+15.2%
Q1 2023$108,465,158
+1.8%
2,003,050
-0.5%
0.05%
-4.2%
Q4 2022$106,567,491
+4.1%
2,013,747
-8.5%
0.05%
-4.0%
Q3 2022$102,385,000
-15.1%
2,200,408
+4.2%
0.05%
-9.1%
Q2 2022$120,586,000
+1980.9%
2,112,587
+2130.6%
0.06%
+2650.0%
Q1 2022$5,795,000
+24.0%
94,710
+6.0%
0.00%0.0%
Q4 2021$4,674,000
+40.4%
89,3100.0%0.00%
+100.0%
Q3 2021$3,329,000
-10.0%
89,310
-1.4%
0.00%0.0%
Q2 2021$3,699,000
+13.8%
90,610
-5.4%
0.00%0.0%
Q1 2021$3,251,000
+8.0%
95,810
+1.3%
0.00%0.0%
Q4 2020$3,009,000
+23.9%
94,6100.0%0.00%0.0%
Q3 2020$2,428,000
+7.2%
94,610
+7.3%
0.00%0.0%
Q2 2020$2,264,000
+108.7%
88,210
+24.9%
0.00%0.0%
Q1 2020$1,085,000
-56.4%
70,610
-2.8%
0.00%0.0%
Q4 2019$2,491,000
+315.9%
72,610
-9.5%
0.00%
Q3 2019$599,000
-34.1%
80,210
+14.6%
0.00%
-100.0%
Q2 2019$909,000
+1.6%
70,010
-4.8%
0.00%0.0%
Q1 2019$895,000
+6.9%
73,5100.0%0.00%0.0%
Q4 2018$837,000
-47.5%
73,5100.0%0.00%0.0%
Q3 2018$1,595,000
+22.8%
73,5100.0%0.00%0.0%
Q2 2018$1,299,000
+37.5%
73,510
+63.7%
0.00%0.0%
Q1 2018$945,000
+45.4%
44,9100.0%0.00%
Q4 2017$650,000
-17.5%
44,910
-10.0%
0.00%
-100.0%
Q3 2017$788,000
+21.0%
49,910
-4.8%
0.00%0.0%
Q2 2017$651,000
-27.7%
52,410
-5.4%
0.00%0.0%
Q1 2017$900,000
+7.7%
55,4100.0%0.00%0.0%
Q4 2016$836,000
-0.9%
55,4100.0%0.00%0.0%
Q3 2016$844,000
-60.8%
55,4100.0%0.00%
-50.0%
Q2 2016$2,151,000
+147.8%
55,410
+77.5%
0.00%
+100.0%
Q1 2016$868,000
-48.3%
31,2100.0%0.00%0.0%
Q4 2015$1,679,000
+34.3%
31,2100.0%0.00%0.0%
Q3 2015$1,250,000
+15.1%
31,210
-8.2%
0.00%0.0%
Q2 2015$1,086,000
+954.4%
34,000
+690.7%
0.00%
Q1 2015$103,000
+312.0%
4,300
+207.1%
0.00%
Q4 2014$25,000
+8.7%
1,400
-17.6%
0.00%
Q3 2014$23,000
-42.5%
1,700
-29.2%
0.00%
Q2 2014$40,0002,4000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2018
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 141,348$10,123,3446.03%
Deep Track Capital, LP 2,000,000$143,240,0004.78%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,165,948$83,505,1963.78%
DCF Advisers, LLC 96,857$6,936,8983.76%
Altium Capital Management LP 71,000$5,085,0203.45%
Bellevue Group AG 3,066,400$219,615,5683.36%
Vahanian & Associates Financial Planning Inc. 9,917$710,2562.81%
First Turn Management, LLC 217,425$15,571,9792.24%
Avoro Capital Advisors LLC 2,255,555$161,542,8492.23%
Exome Asset Management LLC 28,300$2,026,8462.00%
View complete list of INTRA CELLULAR THERAPIES INC shareholders